Abstract
Purpose
Wogonin, a plant flavonoid, has antitumor activity in various cancers. Dysregulation of GSK-3β has been implicated in tumorigenesis and cancer progression. In this study, we investigated the antitumor activity and the mechanistic action of wogonin in human nasopharyngeal carcinoma (NPC) cells.
Methods
The effects of wogonin on the cell survival and apoptosis in NPC cells were investigated by MTS assay, flow cytometry, and PARP cleavage assays. Pharmacological inhibitors (BIO, LiCl, and OA), or small interfering RNA (siRNA) were used to address the expression status of GSK-3β and the anticancer effect of ΔNp63 in NPC cells.
Results
Wogonin was shown to induce dose-dependent cell apoptosis due to the induction of sub-G1-phase cells, PARP cleavage, and downregulation of ΔNp63, a survival factor in NPC cells. Strikingly, the apoptotic effect of wogonin involved GSK-3β inactivation via prominent inhibition of phosphorylation at Tyr216 and slightly increment of phosphorylation at Ser9, while there is no change in total GSK-3β proteins. Dysregulation of GSK-3β caused cell apoptosis was confirmed by pharmacological inhibitors (lithium chloroid, LiCl, and 6-bro-moindirubin-3-oxime, BIO). Administration of okadaic acid (OA, a protein phosphatase inhibitor) that significantly inactivated GSK-3β also induced ΔNp63 downregulation and apoptosis. Targeted silencing of ΔNp63 repressed the phosphorylation of GSK-3β at Tyr216 and sensitized NPC cells to wogonin-induced apoptosis. Furthermore, GSK-3β or PP2A inhibitors enhanced wogonin-induced apoptosis via activation of caspase 3/7.
Conclusion
These results indicate that GSK-3β, as well as ΔNp63, are novel targets for wogonin action and suggest that wogonin might provide a potential therapeutic option in NPC. Further in vitro and in vivo studies will help to clarify the therapeutic role of wogonin in NPC.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Nasopharyngeal carcinoma (NPC), a squamous cell carcinoma, is most commonly diagnosed cancer in southern Asia [1]. While environmental factors and genetic susceptibility play important roles in NPC pathogenesis, the Epstein–Barr virus in particular has been implicated in the molecular abnormalities leading to NPC [2]. ΔNp63 has been shown to be the predominant form of p63 expressed in squamous cell carcinomas, including NPC cells [3, 4]. Overexpression of a ΔNp63 isoform in Rat-1A cells that derived from spontaneously immortalized rat embryo fibroblast increases colony growth in soft agar and xenograft tumor formation in nude mice, suggesting an oncogenic role [5]. Protein phosphate 2A (PP2A) was shown to tether GSK-3β and induce the ability of GSK-3β to phosphorylate its molecular target, β-catenin [6]. It was shown that ΔNp63 associated with GSK-3β and PP2A to form a protein complex in the nuclei and led to an increase in intracellular β-catenin, indicating that ΔNp63 would affect the GSK-3β kinase activity [6]. Moreover, it was shown that inhibition of GSK-3β might regulate ΔNp63 gene expression through β-catenin signaling pathway in a human embryonic kidney cell (HEK 293T) [7]. These studies suggested there is a closely regulated relationship between GSK-3β and ΔNp63. In our previous studies, overexpression of ΔNp63 has shown to play an anti-apoptotic role in NPC cells [8, 9]. However, the role of GSK-3β in NPC is still uninvestigated.
Glycogen synthase kinase 3β (GSK-3β) is a multifunctional serine/threonine kinase, which was first identified as a critical mediator in glycogen metabolism [10]. Dysregulation of GSK-3β activity has been implicated in the regulation of cell fate, protein synthesis, cell mobility, proliferation, and apoptosis [11]. GSK-3β inactivation can exert contrasting effects on cell survival depending on the cell type and the nature of the stimulus [12]. Although it has reported that a proapoptotic role for GSK-3β activation in triterpenoids- and ceramide-induced cell death [12, 13], disruption of the murine GSK-3β gene results in embryonic lethality, and mouse embryonic fibroblast derived from these embryos are more sensitive to cell apoptosis [14]. GSK-3β suppression sensitizes prostate cancer cells to TRAIL-induced caspase-8-mediated apoptosis [15]. Consistent with this finding, GSK-3β inhibition associates with the cell apoptosis in pancreatic cancer cells, gliomablastoma cells and colorectal cancer [16–20].
Phosphorylation has been shown to regulate the activity of GSK-3β that positively regulated by phosphorylation at Tyr 216 (p-GSK-3β(Y216)) and negatively regulated by phosphorylation at Ser 9 (p-GSK-3β(S9)) [13]. P-GSK-3β(S9) by kinases such as Akt inhibits its activity and by protein phosphatase such as PP2A activates its activity [12]. PP2A can revert the phosphorylation of P-GSK-3β(S9) by its phosphatase action [21]. Thus, GSK-3β has been shown to act downstream of PP2A [12]. Recently, it has been shown that higher expression levels of GSK-3β and p-GSK-3β(Y216) were frequently detected in glioblastoma, colorectal cancer cells [19, 20]. Inhibition of GSK-3β induced the apoptosis and attenuated the cell survival that associated with increased expression of p53 and p21, inhibition of cyclin D1 or NF-kB expression [19]. In addition to phosphorylation, protein complex formation also has important regulatory influence on GSK-3β activity, such as Wnt signaling negatively regulates GSK-3β activity by disrupting a protein complex that brings GSK-3β into close proximity with its substrate, β-catenin [22].
Wogonin (5,7-dihydroxy-8-methoxyflavanone) is a flavonoid compound derived from the traditional Chinese medicine of Huang-Qin (Scutellaria radix) with various therapeutic potential including anti-inflammatory [23], anticancer activities [24–28], and its low toxicity to normal tissues [29, 30]. The anticancer activity has been reported in various tumors recognized as a new source of anticancer drugs and new chemotherapy adjuvant to enhance the efficacy of chemotherapy and to ameliorate the effects of cancer chemotherapies [29, 31]. In this study, the effects of wogonin on the cell survival and apoptosis in NPC cells were investigated. Wogonin, pharmacological inhibitors (BIO, LiCl, and OA) [32], or small interfering RNA (siRNA) were used to address the expression status of GSK-3β and the anticancer effect of ΔNp63 in NPC cells. Our data demonstrated that GSK-3β and ΔNp63 might be as a potentially attractive target for human NPC therapy.
Materials and methods
Cell culture and reagents
Human nasopharyngeal carcinoma cell lines NPC-TW076 and NPC-TW039 were isolated from keratinized nasopharyngeal squamous cell carcinoma [33]. The cells were maintained in basal medium (DMEM/F-12 at 1:1 v/v; Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum in a humidified incubator at 37°C under 5% CO2/95% air. Wogonin (>99% pure) were obtained from Wako Chemical Co. (San Francisco, CA, USA). Most chemicals were obtained from Sigma (St. Louis, MO) unless otherwise indicated. 6-Bromoinirubin-3′-oxime (BIO) was purchased from Calbiochem (San Diego, CA). Antibodies to (ADP-ribose) polymerase-1 (PARP-1), GSK-3β, and phosphorylated GSK-3β (Ser9) were purchased from Cell Signaling (Beverly, MA). Antibody to ΔNp63 was purchased from Biolegend (San Diego, CA). Antibody to phosphorylated GSK-3β (Tyr216) was purchased from GenScript (Piscataway, NJ).
Measurement of cell viability
Briefly, 2 × 104 cells per well were plated in 96-well plates and incubated overnight. The cells were then treated with wogonin or inhibitors at indicated concentrations and time course. Alternatively, cells were transiently transfected with appropriate siRNA and cultured at the indicated time points post-transfection. Cell viability was determined by the colorimetric MTS assay using the CellTiter 96® AQueous One Solution Proliferation Assay System from Promega (Madison, WI). After incubation for 2 h at 37°C, the absorbance, which is directly proportional to the number of viable cells in cultures, was measured at 490 nm using a microplate reader.
The sub-G1 cells distribution analysis
PI staining was used to analyze the DNA content. Cells were plated in 35-mm dishes at concentrations determined to yield 60–70% confluence within 24 h. Cells were then treated with wogonin (50 μM) for 24 h. Both the adherent and floating cells were harvested, and the cells were resuspended in PBS, fixed with 70% ethanol, labeled with propidium iodide (PI, 0.05 mg/ml) and incubated at room temperature in the dark for 30 min. DNA content was then analyzed using a FACScan instrument equipped with FACStation running cell Quest software (Becton–Dickinson).
Apoptosis assay
Cell apoptosis was assayed by annexin V–Cy5 and PI staining (BioVision Inc., Mountain View, CA) followed by FACS analysis. The cells were treated with wogonin at the indicated concentrations for 24 h. The cells were pelleted and resuspended in annexin V binding buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4) containing annexin V–Cy5 (1:1,000) and 1 μg/ml PI. After incubation at room temperature for 5 min, the cells were analyzed with a FACSCalibur flow cytometer (Becton–Dickinson, USA). The percentage of total apoptotic events was defined as the sum of the cells in the early stage (annexin-V-Cy5 positive/PI negative) or late stage (annexin-V-Cy5 positive/PI positive) of apoptosis as previously described [9].
Preparation of cell lysates and Western blot analysis
The cells were seeded at a 1 × 106 per 100-mm culture dish. The cells were incubated for 24 h and were treated with wogonin or GSK 3β inhibitors at the desired concentrations. Twenty-four hours after treatment, the cells were washed with ice-cold phosphate-buffered saline and lysed in Mammalian Protein Extraction Reagent (M-PER; Pierce Chemical Co., Rockford, IL). Protein samples (20 μg per lane) were separated on a 10% SDS–polyacrylamide gel and blotted onto polyvinylidene difluoride membranes (Immobilon(TM)-P, Millipore, Bedford, MA), blocked in TTBS and probed with primary antibodies overnight at 4°C. The membranes were then incubated with the appropriate horseradish peroxidase–conjugated secondary antibodies (1:2,000). The immunoreactive protein bands were developed by Enhanced Chemiluminescence (ECL) (Amersham Pharmacia Biotech, Freiburg, Germany).
siRNA transfection
To explore the function of ΔNp63 or GSK-3β in NPC cells, small interfering RNA (siRNA) was used to silence their expressions. The siRNA targeting ΔNp63 mRNA was designed and synthesized by Dharmacon Research Inc. (Lafayette, CO, USA).The siRNA sequence for ΔNp63 targeting was 5′ACAAUGCCCAGACUCAAUU3′. The GSK-3β siRNA and non-targeting siRNA was purchased from Cell Signaling Technology (Beverly, MA, USA; 5′-CUACUUCCUGAAAACAACGTT). The transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The effectiveness of siRNA silencing was assayed by Western blot analysis using anti-ΔNp63 or anti- GSK-3β antibody.
Luminescence-based caspase-3/7 activity assay
Active caspase 3 was assayed with the caspase 3/7-GLO assay (Promega, Madison, WI) according to the manufacturer’s instructions. Cells were plated in triplicate at 2 × 103 per well in white-walled 96-well plates (Becton–Dickinson). Cells were pretreated with inhibitor as described above. Caspase-3/7 activity was measured at 24-h treatment with wogonin. Caspase-Glo 3/7 assay uses a caspase-3/7 tetrapeptide DEVD substrate that produces a luminescent signal on cleavage. Relative light units were measured on an Lmax Microplate Luminometer (Molecular Devices). Experiments were performed in triplicate. Means and standard deviation for 3 independent experiments were shown. For comparison of caspase activity, we designated the level of caspase 3 activity in negative control cells as 1 and expressed the level of caspase 3 activity in the experimental sample relative to the negative control.
Statistical analyses
Data are presented as means ± SEM. The statistical differences were determined using Student–Newman–Keuls Test and Dunn’s Test (Sigma Stat Software Program, Jandel Scientific, San Rafael, CA). A P value of 0.05 or less was considered as significant.
Results
Wogonin inhibits cell growth and blocks cell cycle progression
To examine the possible effect of wogonin on the cell viability in human NPC cells, including NPC-TW076 and NPC-TW039 cells, with colorimetric MTS assay. Cell viability was dose-dependently reduced in both NPC-TW076 and NPC-TW039 cells after wogonin treatment as indicated concentrations for 24 h (Fig. 1a). An IC50 value of NPC-TW076 and NPC-TW039 cells were 34.6 and 30.5 μM, respectively. Next, to determine whether this reduction of cell viability by wogonin was related to the cell apoptosis, the percentage of sub-diploid cells was detected by flow cytometry. Exposure to wogonin (50 μM) for 24 h induced 21.5 and 26.6% of the sub-G1 fraction in NPC- TW076 and NPC-TW039 cells (Fig. 1b). The data indicate that wogonin treatment induced apoptosis of both NPC cell lines.
Wogonin induces the downregulation of ΔNp63 and cell apoptosis
ΔNp63 overexpression promotes the survival and enhances oncogenic growth of NPC cells [8, 9]. To verify whether downregulation of ΔNp63 was responsible for wogonin induction of NPC cell apoptosis, ΔNp63 expression, and poly(ADP-ribose) polymerase (PARP) cleavage were detected in wogonin-treated cell lysates by Western blot. As shown in Fig. 2a, wogonin induced the reduction of ΔNp63 as well as the induction of PARP cleavage was in a dose-dependent manner. Increased cell apoptosis was further confirmed by PI and annexin V staining by analysis of flow cytometry. Figure 2b shows the percentage of annexin V–cy5 binding both NPC cell lines markedly increased after treatment with wogonin at concentrations of 25 and 50 μM for 24 h in both cell lines. These data suggest that an association between ΔNp63 downregulation and apoptotic induction.
Wogonin inhibits the GSK-3β activation
GSK-3β is considered as an active regulator of oncogenic pathways in human cancers as a tumor promoter or a tumor suppressor [20]. To determine whether GSK-3β activation was involved in wogonin-inhibited ΔNp63 expression, the effects of wogonin on the protein level, and phosphorylation status of GSK-3β were examined. GSK-3β activation was measured after NPC cells treated with wogonin (25 and 50 μM) for 24 h. Upon wogonin treatment, the total protein of GSK-3β was unchanged, while its phosphorylation status was obviously affected. Wogonin not only increased p-GSK-3β(S9) but also dramatically decreased p-GSK-3β(Y216) (Fig. 3a). Next, to confirm that the activity of GSK-3β was affected, the Ser37/41 phosphorylation level of β-catenin, a marker of GSK-3β activity, was checked. Figure 3b shows that wogonin caused a dose-dependent dephosphorylation of β-catenin, suggesting a functional blockage of GSK-3β.
GSK-3β inhibitors induce cell apoptosis
NPC-TW076 and NPC-TW039 cells are isolated from keratinized nasopharyngeal squamous cell carcinoma from different patients [33]. It shows no detectable Epstein–Barr virus DNA sequence and the doubling time is 10.5 and 10.8 h, respectively. Since the similar effects of wogonin on inducing cell apoptosis and GSK-3β inactivation in both cell lines, NPC-TW076 cell was used to examine the following molecular events. To determine whether GSK-3β inactivation was responsible for ΔNp63 downregulation and cellular apoptosis, the well-known GSK-3β pharmacological inhibitors, lithium chloride (LiCl), and synthetic, cell-permeable derivative 6-bro- moindirubin-3-oxime (BIO), were applied. NPC-TW076 cell was treated with LiCl or BIO for 2 h prior to treatment with or without wogonin for 24 h, and subsequently, the cell viability and apoptotic effect were measured. Importantly, LiCl and BIO induced viability suppression (Fig. 4a) and cell apoptosis (Fig. 4b). The effects of BIO and LiCl on the phosphorylation status of GSK-3β were further investigated by Western blotting (Fig. 4c). Treatment with LiCl (30 mM) increased p-GSK-3β(S9), with no significant effect on the relative phosphorylation level of GSK-3β at Tyr216. Conversely, BIO (2 μM) significantly reduced the phosphorylation level of GSK-3β at Tyr216 and was no obvious increase in p-GSK-3β(S9) (Fig. 4c). Co-treatment with wogonin did not change the GSK-3β phosphorylation status of BIO treatment, but decreased the relative phosphorylation level of GSK-3β at Tyr216, which was unchanged by LiCl treatment alone. The apoptotic effect of BIO and LiCl were further investigated by Western blotting (Fig. 4d). BIO (2 and 5 μM) as well as LiCl (10 and 30 mM) had a dose-dependent reduction in ΔNp63 expression and increment in PARP cleavage. These data suggest that inactivation of GSK-3β was involved in cell apoptosis.
Inactivated GSK-3β by OA induces cell apoptosis
GSK-3β is shown to act a downstream molecule of PP2A [12]. PP2A induces Ser9 dephosphorylation of GSK-3β and activates it [21]. To examine whether wogonin-induced inhibition of GSK-3β is via PP signaling, okadaic acid (OA, 5 and 10 nM), a protein phosphatases inhibitor, was used to estimate on the basis of presence of the phosphorylated forms of GSK-3β in NPC-TW076 cells. As shown in Fig. 5, OA dose dependently reduced ΔNp63 expression and GSK-3β inactivation via significantly phosphorylation at Ser9 and slightly dephosphorylation at Tyr216. The phosphorylation status of GSK-3β induced by OA was different from the state by wogonin. However, OA-inhibited PP resulted in GSK-3β inactivation and led to cell apoptosis shown by PARP cleavage and ΔNp63 downregulation. OA was also shown to enhance the wogonin-induced apoptotic events. These data clearly indicate that wogonin-inactivated GSK-3β was PP-independent and suggest that inactivation of GSK-3β might have partially contributed to induction of cell apoptosis.
GSK-3β activation is regulated by the level of ΔNp63 expression
To verify the regulation of GSK-3β associated with ΔNp63 in NPC cells, we determined the ΔNp63 expression in GSK-3β siRNA-transfected cells or the GSK-3β phosphorylation status in ΔNp63 siRNA-transfected cells. To our surprise, knockdown of GSK-3β with specific siRNA did not interfere with the expression of ΔNp63 (Fig. 6a), while ΔNp63 siRNA treatment reduced endogenous ΔNp63 expression that resulted in reduction of p-GSK-3β(Y216) (Fig. 6b). Further, ΔNp63 siRNA transfection enhanced the extent of wogonin-inhibited p-GSK-3β(Y216) (Fig. 6c). These data indicate that ΔNp63 expression level might regulate GSK-3β in NPC cells.
Silencing of ΔNp63 with siRNA sensitized NPC cells to wogonin
To further validate the biological significance of the ΔNp63 downregulation involved in wogonin-induced cell apoptosis, NPC cells were transfected with ΔNp63 siRNA for 48 h, and then ΔNp63 expression and cell apoptosis were analyzed. As shown in Fig 7a, targeted inhibition of ΔNp63 with siRNA effectively reduced the expression of ΔNp63, and this effect was enhanced by co-treatment with wogonin. Additionally, silence of ΔNp63 also enhanced wogonin-induced apoptosis evaluated by flow cytometry of annexin-V-stained cells (Fig. 7b), implying that administration of ΔNp63 siRNA facilitated NPC cells to wogonin induction of apoptosis. The data demonstrate that wogonin-induced ΔNp63 downregulation resulted in cell apoptosis.
Wogonin induces the activation of caspase 3/7
To examine whether pharmacological inhibitors enhanced wogonin-induced apoptosis via activation of caspase 3/7, NPC-TW076 cell was treated with BIO, LiCl, or OA for 2 h prior to treatment with or without wogonin (50 μM) for 24 h, then cell was subjected to analyze the caspase 3/7 activity using the caspase 3/7 Glo assay. As shown in Fig. 8, wogonin and GSK-3β inhibitors treatment alone increased caspase 3/7 activity about 0.2 ~ 0.8-fold compared with control group (wogonin-untreated group). Pretreatment cells with the inhibitors (LiCl, BIO, and OA) for 2 h significantly enhanced the wogonin-induced caspase 3/7 activity (Fig. 8). Theses inhibitors were shown to enhance the wogonin-induced cell apoptosis in Figs. 4b and 5. Taken together, treatment with wogonin or GSK-3β inhibitors induced cell apoptosis via activation of caspase 3.
Discussion
Wogonin is an effective drug with antiproliferative and apoptotic activity in human cancer cells, including lung epithelial cancer cells [26], colon cancer cells [27], leukemia cells [24, 28, 34], malignant lymphocytes [30], and breast cancer cells [25]. However, its healing mechanisms are still largely unknown. This study presented molecular mechanisms of wogonin responsible for the apoptotic effects, by inducing ΔNp63 downregulation and GSK-3β inactivation in NPC cells. We found inactivation of GSK-3β by its inhibitors (LiCl, BIO, and OA), and wogonin was associated with ΔNp63 downregulation that led to cell apoptosis. Depletion of ΔNp63 protein by siRNA inactivated GSK-3β via inhibition of phosphorylation at Tyr216 and enhanced wogonin-induced cell apoptosis. These data indicate GSK-3β and ΔNp63 are the molecular targets of wogonin and suggest that wogonin acts as a promising therapeutic option for NPC.
Downregulation of ΔNp63 by siRNA induces NPC cell apoptosis via activation of caspase 3 [9]. The present study indicates that wogonin acts like GSK-3β inhibitors that induced cell apoptosis. The involvement pathway is shown to induce the GSK-3β inactivation, ΔNp63 downregulation, caspase 3 activation, and the increment of PARP cleavage. These effects of wogonin might contribute to the increment of the sub-G1 cells and annexin-V-staining cells. Especially, this study also indicates silence of ΔNp63 expression induced the Tyr 216 dephosphorylation of GSK-3β. The role of GSK-3β in the regulation of apoptosis is controversial [35]. Recent reports on other cancers, including pancreatic cancer [16], medullary thyroid cancer [36], and glioblastoma cells [19], have shown to inhibit the GSK-3β kinase activity by inhibitors or genetic depletion of its protein by siRNA that lead to decrease in cancer cell proliferation and survival. Consistent with theses studies, this study shows wogonin might exert its apoptotic effect through inhibition of GSK-3β/ΔNp63 pathway in NPC cells.
GSK-3β is a dual specificity kinase differentially regulated by Tyr and Ser phosphorylation and correlated with a net inactivation of the enzyme. Subsequent dephosphorylation at Ser 9 residue restores activity, whereas dephosphorylation at Tyr216 residue leads to further inactivation [37]. This study shows wogonin-inactivated GSK-3β with phosphorylation or dephosphorylation of GSK-3β at different residues resulted in cell apoptosis that was evidenced by pharmacological inhibitors (LiCl and BIO). LiCl inhibits GSK-3β by acting as a competitive inhibitor of Mg2+ inducing Ser9 autophosphorylation [38]. In addition, PKA is shown to function as a GSK-3 kinase that, in parallel with PKB, controls the activity of the multifunctional enzyme GSK-3 [39]. Increasing evidence suggests that GSK-3β activity is increased by Tyr216 phosphorylation [18, 20]. Phosphorylation of GSK-3β is an intramolecular autophosphorylation event in the cells [40] or by Pyk2, a tyrosine kinases [41]. Dephosphorylation at Tyr216 diminishes its activity [41]. BIO is a potent pharmacological inhibitor of GSK-3β that inhibits its phosphorylation at Tyr216, a GSK-3β activation site [42]. With BIO treatment, the apoptosis was evaluated to be associated with dephosphorylation of GSK-3β at Tyr216 in NPC cells. Thus, wogonin-induced apoptosis like BIO’s effect that concomitantly related with significantly dephosphorylation of GSK-3β at Tyr216. Comparing with LiCl, BIO, OA, and wogonin, this study indicates GSK-3β inactivation that the absence of phosphorylation at Tyr216 and/or the presence of phosphorylation at Ser9 would play an important role for induction of cancer-specific apoptosis. Thus, wogonin acts like LiCl and BIO displayed remarkable selective inhibition of GSK-3β [42].
Dephosphorylation Tyr216 or phosphorylation Ser9 of GSK-3β is critical for the specification of cell fate [11]. Wogonin induced deleterious signals against cancer cell viability and survival that was evidenced by downregulation of ΔNp63. ΔNp63 is frequently overexpressed in NPC cells, and its downregulation exhibits proapoptotic function via increasing the caspase 3 activity and PARP cleavage [4, 8, 9]. NPC cell that treated with LiCl or BIO induced GSK-3β inactivation, ΔNp63 downregulation, caspase 3/7 activation, and apoptosis. However, this event seems due to the effect of GSK-3β inactivation (phosphorylation at Ser9 or dephosphorylation at Tyr216) and is not related with the level of GSK-3β protein. GSK-3β is shown to regulate ΔNp63 gene expression through β-catenin signaling pathway in HEK 293T cells [7]. However, there was no change on the expression level of ΔNp63 while NPC cell treated with GSK-3β siRNA. Wogonin treatment also did not cause significantly change on the total protein of GSK-3β. In addition, the effect of GSK-3β inactivation induced by OA also responses to the downregulation of ΔNp63. These findings indicate the level of GSK-3β protein might not involve in the regulation of ΔNp63 gene expression, but a change in the status of phosphorylation might associate with the regulation of ΔNp63 in NPC cells.
An alternative mechanism that could lead to disruption of GSK-3β activity is a substrate trap mechanism by a complex associated with the PP2A, ΔNp63, and GSK-3β [6]. Δ protein is shown to bind to the N terminus of B56α, a catalytic unit of PP2A and forms a complex with GSK-3β, leading to the proposal that the expression of ΔNp63 reduces the PP2A-dependent activation of GSK-3β[6]. However, in this study, we find that target silence of ΔNp63 induced GSK-3β inactivation via inhibition of Tyr216 phosphorylation in NPC-TW076 cells. Further, knockdown of ΔNp63 in the presence of wogonin was shown to account for the enhancing effect of GSK-3β inhibition. These findings suggest that ΔNp63 protein expression might regulate the GSK-3β activation. ΔNp63 expression as well as GSK-3β activation might play a role in the pathogenesis of NPC cells.
In the present study, the proapoptotic role of wogonin in NPC cells is explored. The signaling mechanisms of wogonin are shown by GSK-3β inactivation and ΔNp63 downregulation that lead to cell apoptosis. This study also shows there is a closely regulation of GSK-3β activation associated with the ΔNp63 expression. Thus, wogonin is suggested to have potential therapeutic application in the treatment of NPC cancer.
References
Lo KW, To KF, Huang DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5:423–428
Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM (2008) Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis. Head Neck 30:946–963
Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45–56
Crook T, Nicholls JM, Brooks L, O’Nions J, Allday MJ (2000) High level expression of Delta N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19:3439–3444
Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill D, Ratovitski EA, Jen J, Sidransky D (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97:5462–5467
Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D (2002) Np63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 1:369–380
Chu WK, Dai PM, Li HL, Chen JK (2008) Glycogen synthase kinase-3beta regulates DeltaNp63 gene transcription through the beta-catenin signaling pathway. J Cell Biochem 105:447–453
Chiang CT, Chu WK, Chow SE, Chen JK (2009) Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol 219:117–122
Chow SE, Wang JS, Chuang SF, Chang YL, Chu WK, Chen WS, Chen YW (2010) Resveratrol-induced p53-independent apoptosis of human nasopharyngeal carcinoma cells is correlated with the downregulation of [Delta]Np63. Cancer Gene Ther 17:872–882
Dong JJ, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F (2005) Role of glycogen synthase kinase 3{beta} in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65:1961–1972
Luo J (2009) Glycogen synthase kinase 3[beta] (GSK3[beta]) in tumorigenesis and cancer chemotherapy. Cancer Lett 273:194–200
Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, Lin YS (2007) GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci 120:2935–2943
Vene R, Larghero P, Arena G, Sporn M, Albini A, Tosetti F (2008) Glycogen synthase kinase 3{beta} regulates cell death induced by synthetic triterpenoids. Cancer Res 68:6987–6996
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR, Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000) Requirement for glycogen synthase kinase-3[beta] in cell survival and NF-kappaB activation. Nature 406:86–90
Liao X, Zhang L, Thrasher JB, Du J, Li B (2003) Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2:1215–1222
Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD (2006) Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 12:5074–5081
Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD (2005) Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65:2076–2081
Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68:6643–6651
Miyashita K, Awakami KK, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada JI, Minamoto T (2009) Potential therapeutic effect of glycogen synthase kinase 3{beta} inhibition against human glioblastoma. Clin Cancer Res 15:887–897
Shakoori A, Ougolkov AV, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T (2005) Deregulated GSK3[beta] activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334:1365–1373
Hernández F, Langa E, Cuadros R, Avila J, Villanueva N (2010) Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 344:211–215
Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95–102
Chang YL, Shen JJ, Wung BS, Cheng JJ, Wang DL (2001) Chinese herbal remedy wogonin inhibits monocyte chemotactic protein-1 gene expression in human endothelial cells. Mol Pharmacol 60:507–513
Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki SI, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A (2007) Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett 245:269–274
Chung HY, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ, Jang KS, Jeon SJ, Son KH, Kong G (2008) Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitroand in nude mice xenografts. Int J Cancer 122:816–822
Chen L, Hung LY, Tsai KW, Pan YS, Tsai YD, Li YZ, Liu YW (2008) Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells. Mol Nutr Food Res 52:1349–1357
Lee DH, Kim C, Zhang L, Lee YJ (2008) Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 75:2020–2033
Zhang HW, Yang Y, Zhang K, Qiang L, Yang L, Yang L, Hu Y, Wang XT, You QD, Guo QL (2008) Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKC[delta] phosphorylation. Eur J Pharmacol 591:7–12
Li-Weber M (2009) New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 35:57–68
Baumann S, Fas SC, Giaisi M, Muller WW, Merling A, Gulow K, Edler L, Krammer PH, Li-Weber M (2008) Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLC{gamma}1- and Ca2+ -dependent apoptosis. Blood 111:2354–2363
Enomoto R, Koshiba C, Suzuki C, Lee E (2010) Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol. doi:10.1007/s00280-010-1396-8
Meijer L, Flajolet M, Greengard P (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25:471–480
Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM, Chuang SM (1990) Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 62:713–724
Chow JM, Huang GC, Shen SC, Wu CY, Lin CW, Chen YC (2008) Differential apoptotic effect of wogonin and nor-wogonin via stimulation of ROS production in human leukemia cells. J Cellr Biochem 103:1394–1404
Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79:173–189
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H (2007) Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 6:1151–1158
Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269:14566–14574
Meijer L (2004) Mediterranean purple indirubins: a source of GSK-3 inhibitors. Med Sci (Paris) 20:516–518
Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 97:11960–11965
Cole A, Frame S, Cohen P (2004) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 377:249–255
Sayas C, Ariaens A, Ponsioen B, Moolenaar WH (2006) GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell 17:1834–1844
Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, VonicaCA BrivanlouA, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P (2003) GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem Biol 10:1255–1266
Acknowledgments
This work was supported by funding from the Chang Gung Memorial Hospital to SE Chow (Grant Number: CMRPD 180331).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chow, SE., Chang, YL., Chuang, SF. et al. Wogonin induced apoptosis in human nasopharyngeal carcinoma cells by targeting GSK-3β and ΔNp63. Cancer Chemother Pharmacol 68, 835–845 (2011). https://doi.org/10.1007/s00280-010-1552-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1552-1